HIIFS
VTGN icon

Harel Insurance Investments & Financial Services’s VistaGen Therapeutics VTGN Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,667
Closed -$1.42M – 874
2021
Q1 		$1.42M Buy
+6,667
New +$445K 0.03% 301

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harel Insurance Investments & Financial Services's VTGN Position: Q2 2021 in Review

Harel Insurance Investments & Financial Services sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 6,667 shares — an estimated $1.42M sold.

Harel Insurance Investments & Financial Services first reported a position in VTGN in Q1 2021 and held it in 1 quarter. The position peaked at $1.42M in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • Harel Insurance Investments & Financial Services reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 6,667 VistaGen Therapeutics shares in Q2 2021, an estimated $1.42M.
  • Harel Insurance Investments & Financial Services first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's VistaGen Therapeutics position peaked at $1.42M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2021, filed 26 Jul 2021.